GBP IP, LLC
Records under this name other than patents GBP IP, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,790,641 | Lentiviral vector particles resistant to complement inactivation Formerly held Term ended Term ended Apr 29, 2023 · From the USPTO record | Term ended | Term ended Apr 29, 2023 | From the USPTO record |
| US 6,863,884 | Pseudotyped retroviral vectors Formerly held Term ended Term ended Apr 29, 2023 · From the USPTO record | Term ended | Term ended Apr 29, 2023 | From the USPTO record |
| US 8,652,837 | Method and means for producing high titer, safe, recombinant lentivirus vectors Formerly held Term ended Term ended Feb 9, 2023 · From the USPTO record | Term ended | Term ended Feb 9, 2023 | From the USPTO record |
| US 7,179,903 | Liver specific transcriptional enhancer Formerly held Term ended Term ended Jan 17, 2023 · From the USPTO record | Term ended | Term ended Jan 17, 2023 | From the USPTO record |
| US 6,808,905 | Lentiviral vectors encoding clotting factors for gene therapy Formerly held Term ended Term ended Jul 16, 2022 · From the USPTO record | Term ended | Term ended Jul 16, 2022 | From the USPTO record |
| US 7,745,179 | Lentiviral vectors featuring liver specific transcriptional enhancer and methods of using same Formerly held Term ended Ended no later than May 14, 2022 · From the USPTO record | Term ended | Ended no later than May 14, 2022 | From the USPTO record |
| US 6,797,512 | Selection system for generating efficient packaging cells for lentiviral vectors Formerly held Term ended Term ended Sep 12, 2021 · From the USPTO record | Term ended | Term ended Sep 12, 2021 | From the USPTO record |
| US 7,250,299 | Method and means for producing high titer, safe, recombinant lentivirus vectors Formerly held Term ended Term ended Apr 26, 2020 · From the USPTO record | Term ended | Term ended Apr 26, 2020 | From the USPTO record |
| US 6,165,782 | Method and means for producing high titer, safe, recombinant lentivirus vectors Formerly held Term ended Term ended Mar 18, 2019 · From the USPTO record | Term ended | Term ended Mar 18, 2019 | From the USPTO record |
| US 6,218,187 | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells Formerly held Term ended Term ended Mar 11, 2019 · From the USPTO record | Term ended | Term ended Mar 11, 2019 | From the USPTO record |